JPRN-UMIN000004327已完成2 期
Phase II Study of induction Carboplatin+Paclitaxel+Bevacizumab combination therapy for stage III Non-Small-Cell Lung Cancer (NSCLC) - Phase II Study of induction Carboplatin+Paclitaxel+Bevacizumab combination therapy for stage III NSCLC (TCOG1002)
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)History of active double cancer within 5 years 2)Overt infection 3)History of hemoptysis 4)With great vessel invasion 5)Cavity in tumor 6)Receiving anticoagulant drug(except Aspirin within 324mg/day) 7)Uncontrollable Gastrointestinal ulceration 8)Current or previous(within the last 1 year)history of GI perforation 9)Severe cardiac disease 10)History of Arterial thromboembolism within 1year 11)Interstitial pneumonia or pulmonary fibrosis detectable on X-ray 12)Peripheral neuropathy > Grade2 13)Major surgical procedure 14)With a history of drug sensitivity 15)History of pregnancy or lactation 16)No intention to practice birth control 17)Patients whose participation in the trial is judged to be inappropriate by the attending doctor
研究者
相似试验
已完成
2 期
A Phase II Study of carboplatin plus paclitaxel for advanced thymic cancerThymic cancerJPRN-UMIN000001358West Japan Oncology Group40
进行中（未招募）
不适用
Study of Carboplatin-Paclitaxel, with or without ISIS 183750 (an eIF4E Inhibitor), in Patients with Stage IV Non-Small Cell Lung Cancer, Phase 1b/2EUCTR2010-022240-21-HUIsis Pharmaceuticals Inc.118
进行中（未招募）
1 期
A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast CancerPreviously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)MedDRA version: 20.0Level: PTClassification code 10006198Term: Breast cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10075566Term: Triple negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004651-23-FRInstitut Jules Bordet180
招募中
1 期
A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast CancerPreviously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)MedDRA version: 20.0Level: LLTClassification code: 10027475Term: Metastatic breast cancer Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10075566Term: Triple negative breast cancer Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10006198Term: Breast cancer recurrent Class: 100000004864CTIS2024-511850-34-00Institut Jules Bordet209
招募中
2 期
A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer2024-511850-34-00Institut Jules Bordet209